[Microscopic colitis associated with celiac disease probably triggered by the administration of venlafaxine]

D Béchade1, T Carmoi, S Bonnefoy

  • 1Service de clinique médicale, hôpital du Val-de-Grâce, 74, boulevard de Port-Royal, 75230 Paris cedex 05, France. dominique.bechade94@orange.fr

La Revue De Medecine Interne
|May 27, 2008
PubMed

Insights

The rare association between microscopic colitis and celiac disease was observed in a 67-year-old patient after venlafaxine administration. Pathophysiologic hypotheses for this rare gastrointestinal disorder link are discussed.

Area of Science:

  • Gastroenterology
  • Clinical Case Reports
  • Pharmacology

Background:

  • Microscopic colitis and celiac disease are distinct gastrointestinal conditions.
  • The co-occurrence of these two conditions is exceptionally rare in clinical practice.
  • Understanding rare disease associations is crucial for comprehensive patient care.

Observation:

  • A 67-year-old patient presented with symptoms potentially related to both microscopic colitis and celiac disease.
  • The patient had recently been administered venlafaxine, a serotonin-norepinephrine reuptake inhibitor.
  • This case highlights a potential, albeit uncommon, drug-induced or associated phenomenon.

Findings:

  • The case describes the simultaneous presentation of microscopic colitis and celiac disease.
  • Venlafaxine administration preceded the observed clinical scenario.
  • The study explores potential pathophysiologic mechanisms linking these conditions and the medication.

Implications:

  • This case expands the known spectrum of rare gastrointestinal associations.
  • It prompts consideration of venlafaxine in the differential diagnosis for patients with unexplained gastrointestinal symptoms and potential celiac disease or microscopic colitis.
  • Further research into drug-induced gastrointestinal pathologies is warranted.

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Irritable Bowel Syndrome01:23

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...